COHERUS BIOSCIENCES I

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

22 May 2023 08:30:00 By Nasdaq GlobeNewswire

Coherus Prices Public Offering of Common Stock

16 May 2023 06:50:00 By Nasdaq GlobeNewswire

Coherus Announces Proposed Public Offering of Common Stock

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

08 May 2023 16:05:02 By Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in May

04 May 2023 16:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

01 May 2023 16:07:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

27 Apr 2023 08:05:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

06 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

FDA Approves UDENYCA® Autoinjector

06 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in March

01 Mar 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

28 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

15 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

13 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

03 Feb 2023 17:30:09 By Nasdaq GlobeNewswire

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

09 Jan 2023 08:20:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:01:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

24 Dec 2022 00:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

08 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

01 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

12 Oct 2022 07:30:00 By Nasdaq GlobeNewswire